TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction

Carcinogenesis

Volumn 29, Issue 8, 2008, Pages 1509-1518

  Yuen, Hiu Fung ^a,b   Kwok, Wai Kei ^b   Chan, Ka Kui ^a   Chua, Chee Wai ^b   Chan, Yuen Piu ^a   Chu, Ying Ying ^c   Wong, Yong Chuan ^b   Wang, Xianghong ^b   Chan, Kwok Wah ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF HOMOLOG 1; PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR TWIST;

ARTICLE; BONE CELL; BONE DEVELOPMENT; BONE METASTASIS; BONE MINERALIZATION; BONE REMODELING; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL ACTIVITY; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; EPITHELIUM; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MESENCHYME; METASTASIS POTENTIAL; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; UPREGULATION;

3T3 CELLS; ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE NEOPLASMS; CALCIFICATION, PHYSIOLOGIC; CELL LINE; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA PRIMERS; GENES, REPORTER; HUMANS; MALE; MICE; NUCLEAR PROTEINS; OSTEOBLASTS; OSTEOGENESIS; PLASMIDS; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TWIST TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 49649097767     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn105     Document Type: Article

References (49)

1. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Career J. Clin., 57, 43-66.
2. Klotz,L. (2005) Active surveillance for prostatc cancer: For whom? J. Clin. Oncol., 23, 8165-8169.
3. Denmeade,S.R. et al. (20041) Development of prostate cancer treatment: The good news. Prostate, 58, 211-224.
4. Saad,F. et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst., 94, 1458-1468.
5. Saad,F. et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst., 96 879-882.
6. Loberg,R. et al. (2005) A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J. Cell. Biochem., 96, 439-446.
7. Keller,E.T. et al. (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell. Biochem., 91, 718-729.
8. Hall,C.L. et al. (2006) Role of Wnts in prostate cancer bone metastases. J. Cell. Biochem., 97, 661-672.
9. Guise,T.A. et al. (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res., 12, 6213s-6216s.
10. Chen,G. et al. (2004) Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer, 101 1345-1356.
11. Schwaninger,R. et al. (2007) Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am. J. Pathol., 170, 160-175.
12. Hall,C.L. et al. (2005) Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res., 65, 7554-7560.
13. Liu,X.H. et al. (2007) Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res., 67, 5747-5753.
14. Dorai,T. et al. (2004) Therapeutic potential of curcumin in prostate cancer-V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate, 60 1-17.
15. Koeneman,K.S. et al. (1999) Osteomimetic properties of prostate cancer cells: A hyppothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39, 246-261.
16. Knerr,K. et al. (2004) Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int. J. Cancer, 111, 152-159.
17. Zayzafoon,M. et al. (2004) Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem., 279, 3662-3670.
18. Huang,W.C. et al. (2005) Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway. Cancer Res., 65, 2303-2313
19. Barnes,G.L. et al. (2003) Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res., 63, 2631-2637.
20. Barnes,G.L. et al. (2004) Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res., 64, 4506-4513.
21. Javed,A. et al. (2005) Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc. Natl Acad. Sci. USA, 102, 1454-1459.
22. Brubaker,K.D. et al. (2003) Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate, 56, 13-22.
23. Murray,S.S. et al. (1992) Expression of helix-loop-helix regulatory genes during differentiation of mouse osteoblastic cells. J. Bone Miner. Res., 7, 1131-1138.
24. Rice,D.P. et al. (2000) Integration of FGF and TWIST in calvarial bone and suture development. Development, 127, 1845-1855.
25. Lee,M.S. et al. (1999) TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J. Cell. Biochem., 75, 566-577.
26. Yousfi,M. et al. (2002) TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts. Biochem. Biophys. Res. Commun., 297, 641-644.
27. Bialek,P. et al. (2004) A twist code determines the onset of osteoblast differentiation. Dev. Cell, 6, 423.
28. Ishii,M. et al. (2003) Msx2 and Twist cooperatively control the development of the neural crest-derived skeletogenic mesenchyme of the murine skull vault. Development, 130, 6131-6142.
29. Komori,T. (2006) Regulation of osteoblast differentiation by transcription factors. J. Cell. Biochem., 99, 1233-1239.
30. Wang,X. et al. (2004) Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene, 23, 474-482.
31. Kwok,W.K. et al. (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res., 65 5153-5162.
32. Yang,J. et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117, 927-939.
33. Ma,L. et al. (2007) Tumour invasion and metastasis initiated by micro-RNA-10b in breast cancer. Nature, 449, 682-688.
34. Yuen,H.F. et al. (2007) Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology, 50, 648-658.
35. Valsesia-Wittmann,S. et al. (2004) Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell, 6, 625-630.
36. Ling,M.T. et al. (2005) Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis, 26, 1668-1676.
37. Dai,J. et al. (2005) Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res., 65, 8274-8285.
38. Corey,E. et al. (2005) Osteoprotegerin in prostate cancer bone metastasis. Cancer Res., 65, 1710-1718.
39. Sramkoski,R. et al. (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell. Dev. Biol. Anim., 35, 403-409.
40. Zeitlinger,J. et al. (2007) Whole-genome ChIP-chip analysis of Dorsal, Twist, and Snail suggests integration of diverse patterning processes in the Drosophila embryo. Genes Dev., 21, 385-390.
41. Chamorro,M. et al. (2005) FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J., 24, 73-84.
42. Hinoi,E. et al. (2006) Runx2 inhibits chondrocyte proliferation and hypertrophy through its expression in the perichondrium. Genes Dev., 20, 2937-2947.
43. Robling,A.G. et al. (2006) Biomechanical and molecular regulation of bone remodeling. Annu. Rev. Biomed. Eng., 8, 455-498.
44. Hadjidakis,D.J. et al. (2006) Bone remodeling. Ann. N. Y. Acad. Sci., 1092, 385-396.
45. Howe,L.R. et al. (2003) Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res., 63, 1906-1913.
46. Reinhold,M.I. et al. (2006) The Wnt-inducible transcription factor Twist1 inhibits chondrogenesis. J. Biol. Chem., 281, 1381-1388.
47. Zi,X. et al. (2005) Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res., 65, 9762-9770.
48. Ganguly,A. et al. (2005) Drosophila WntD is a target and an inhibitor of the Dorsal/Twist/Snail network in the gastrulating embryo. Development, 132, 3419-3429.
49. Hayashi,M. et al. (2007) Comparative roles of Twist-1 and Id1 in transcriptional regulation by BMP signaling. J. Cell Sci., 120 1350-1357.